MX9400434A - Potenciamiento de temozolomida en celulas de tumores humanos. - Google Patents

Potenciamiento de temozolomida en celulas de tumores humanos.

Info

Publication number
MX9400434A
MX9400434A MX9400434A MX9400434A MX9400434A MX 9400434 A MX9400434 A MX 9400434A MX 9400434 A MX9400434 A MX 9400434A MX 9400434 A MX9400434 A MX 9400434A MX 9400434 A MX9400434 A MX 9400434A
Authority
MX
Mexico
Prior art keywords
temozolomide
enhancement
tumor cells
human tumor
thermozolomide
Prior art date
Application number
MX9400434A
Other languages
English (en)
Inventor
Amanda Jean Watson
Joseph Anthony Rafferty
Geoffrey Paul Margison
John Colin Baer
Azadeh Alison Freeman
Edward Stuart Newlands
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of MX9400434A publication Critical patent/MX9400434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La Toxicidad de la termozolomida, un agente antitumoral útil en el tratamiento de varios neoplasmas de mamíferos, puede ser potenciada por la administración previa de un agente inhibidor de Atasa, esto es, 06-bencilguanina.
MX9400434A 1993-01-14 1994-01-13 Potenciamiento de temozolomida en celulas de tumores humanos. MX9400434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14

Publications (1)

Publication Number Publication Date
MX9400434A true MX9400434A (es) 1994-07-29

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9400434A MX9400434A (es) 1993-01-14 1994-01-13 Potenciamiento de temozolomida en celulas de tumores humanos.

Country Status (20)

Country Link
EP (2) EP0679086A1 (es)
JP (1) JPH08505615A (es)
KR (1) KR100352046B1 (es)
CN (1) CN1277541C (es)
AU (1) AU5838494A (es)
CA (1) CA2153775C (es)
CZ (1) CZ286550B6 (es)
FI (1) FI953423A (es)
HU (1) HUT72665A (es)
IL (1) IL108328A (es)
MX (1) MX9400434A (es)
MY (1) MY116474A (es)
NO (1) NO952781L (es)
PL (1) PL175842B1 (es)
RU (1) RU2148401C1 (es)
SK (1) SK282452B6 (es)
TW (1) TW414710B (es)
UA (1) UA29466C2 (es)
WO (1) WO1994015615A1 (es)
ZA (1) ZA94248B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
PE20001320A1 (es) * 1998-12-07 2000-12-06 Schering Corp Uso de composiciones microcristalinas de temozolomida en el tratamiento de canceres
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
JP4077794B2 (ja) * 2002-02-22 2008-04-23 シェーリング コーポレイション 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
AU2003240496B2 (en) * 2002-05-31 2008-01-10 Eisai Inc. Combination chemotherapy with chlorotoxin
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
LT2531206T (lt) 2010-02-04 2017-09-25 Morphotek, Inc. Chlorotoksino polipeptidai ir konjugatai ir jų naudojimas
EP2569330B1 (en) 2010-05-11 2016-09-28 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
AU2013359429A1 (en) 2012-12-10 2015-07-09 Fred Hutchinson Cancer Research Center Methods for screening
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof

Also Published As

Publication number Publication date
PL309915A1 (en) 1995-11-13
EP0679086A1 (en) 1995-11-02
EP0922458A1 (en) 1999-06-16
NO952781D0 (no) 1995-07-13
NO952781L (no) 1995-09-13
AU5838494A (en) 1994-08-15
HU9502117D0 (en) 1995-09-28
PL175842B1 (pl) 1999-02-26
RU2148401C1 (ru) 2000-05-10
CN1117711A (zh) 1996-02-28
JPH08505615A (ja) 1996-06-18
CA2153775C (en) 2000-11-14
WO1994015615A1 (en) 1994-07-21
HUT72665A (en) 1996-05-28
MY116474A (en) 2004-02-28
IL108328A (en) 2010-05-31
SK89295A3 (en) 1996-06-05
TW414710B (en) 2000-12-11
ZA94248B (en) 1994-07-13
FI953423A0 (fi) 1995-07-13
CA2153775A1 (en) 1994-07-21
FI953423A (fi) 1995-08-23
CN1277541C (zh) 2006-10-04
CZ286550B6 (cs) 2000-05-17
KR960700063A (ko) 1996-01-19
IL108328A0 (en) 1994-04-12
KR100352046B1 (ko) 2003-09-03
SK282452B6 (sk) 2002-02-05
UA29466C2 (uk) 2000-11-15
CZ179795A3 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
MX9200675A (es) Derivados de 2,4-diaminoquinazolinas para mejorar la actividad antitumoral.
SI0882021T1 (en) New phenanthridines
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
DE69835824D1 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
DK0701440T3 (da) Tri(platin)komplekser
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
IL131478A0 (en) Methods for treatment of scar tissue
ES2012547A6 (es) Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas.
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
ZA9610073B (en) Method of using beta-interferons to treat restenosis
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
KR940011002A (ko) 식이성 무기조성물 및 제조방법
AU128055S (en) Singlet

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees